Market Share of Asia - Pacific Human Insulin Industry
The Asia-Pacific Human Insulin Market is highly consolidated, with three major manufacturers having a large market share. However, many local companies have brought biosimilar insulin at a much lower price. Mergers and acquisitions between the players in the recent past helped the companies strengthen their market presence. Sandoz partnered with Gan&Lee for the commercialization of insulin developed by Gan&Lee. Sandoz will likely fully commercialize these medicines in the EU, the United States, Switzerland, Japan, South Korea, Canada, Australia, and New Zealand.
Asia-Pacific Human Insulin Market Leaders
-
Novo Nordisk
-
Eli Lilly
-
Sanofi
-
Biocon
-
Gan & Lee
*Disclaimer: Major Players sorted in no particular order
